<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377594</url>
  </required_header>
  <id_info>
    <org_study_id>200212IDEALAF</org_study_id>
    <nct_id>NCT04377594</nct_id>
  </id_info>
  <brief_title>Ablation of Fibrotic Areas in Patients With Persistent Atrial Fibrillation.</brief_title>
  <acronym>IDEAL-AF</acronym>
  <official_title>Individually DEsigned Ablation of Low Voltage Areas in Patients With Persistent Atrial Fibrillation, a Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief summary: The objective of this study is to compare two different ablation strategies in
      participants with persistent atrial fibrillation and fibrotic areas in the left atrium. The
      participant will be randomized to pulmonary vein isolation or pulmonary vein isolation plus
      ablation of fibrotic areas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Atrial fibrillation (AF) is the most common arrhythmia in clinical practice with a prevalence
      of 2-3 percent in the population. Catheter ablation performing pulmonary vein isolation (PVI)
      is an established treatment, which aim to eliminate triggers from the pulmonary veins. This
      treatment is successful in most patients with paroxysmal AF. In many patients, especially the
      patients with persistent AF, this treatment is not sufficiently to achieve freedom from
      arrhythmia and symptoms.

      There are several studies showing that fibrosis in the left atrium (LA) is an independent
      factor to relapse in AF after PVI. The fibrotic areas can be detected by measuring the
      voltage in the left atrium and creating a voltage map. There are non-randomized studies that
      suggest better results regarding reduction of arrhythmia burden after ablating the low
      voltage areas (LVAs). This ablation strategy is commonly used in clinical praxis although
      there are no randomized studies in this field.

      Aim:

      The objective of this study is to compare two different ablation strategies in participants
      with persistent atrial fibrillation and fibrotic areas in the left atrium. The participant
      will be randomized to PVI versus PVI plus ablation of LVAs.

      The primary endpoint is freedom of atrial arrhythmias after 1 to 2 ablation procedures within
      6 months measured at 12 months after the first ablation procedure without antiarrhythmic
      drugs. Secondary endpoints will be atrial arrhythmia burden, health related quality of life
      measured by AFEQT score, and RAND 36 and periprocedural complications; death, stroke/ TIA,
      tamponade, atrio-esophageal fistula, and atrioventricular block.

      Study design:

      Randomized controlled multicenter trial. The study will be single blinded. All the
      participants will undergo PVI and the substrate map will be collected during atrial pacing.
      The patients with LVA will be randomized in a 1:1 fashion to; PVI plus ablation of LVA or PVI
      alone. Follow up visits will be at 3, 6, 12, 18 and 24 months. Before ablation and at every
      follow up visit the participants will fill in arrhythmia symptom specific questionnaires
      (AFEQT and ASTA) and questionnaire about quality of life (RAND 36). The participants will
      register arrhythmia with a heart monitoring system if symptoms of arrhythmia and two times
      daily during two weeks before every follow up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmia</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial arrhythmias &gt;30 seconds at 12 months after 1 or 2 ablation procedures within 6 months without antiarrhythmic drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmia after 1 Ablation Procedure without Antiarrhythmic Drugs (AAD)</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial arrhythmias &gt;30 seconds at 12 months after 1 ablation procedure without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmia after 1 Ablation Procedure with/ without AAD</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial arrhythmias &gt;30 seconds at 12 months after 1 ablation procedure with or without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmia after 1 or 2 Ablation Procedures with/ without AAD</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial arrhythmias &gt;30 seconds at 12 months after 1 or 2 ablation procedures with or without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Fibrillation</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial fibrillation &gt;30 seconds at 12 months after 1 or 2 ablation procedures without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Symptomatic Atrial Arrhythmias</measure>
    <time_frame>From 3 months (blanking period) to 12 months after the first ablation procedure</time_frame>
    <description>Freedom from documented symptomatic atrial arrhythmias &gt;30 seconds at 12 months after 1 or 2 ablation procedures with or without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmias without AAD</measure>
    <time_frame>From 3 months (blanking period) to 24 months after the first ablation procedure</time_frame>
    <description>Freedom from documented atrial arrhythmias &gt;30 seconds at 24 months after 1 or several ablation procedures without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Freedom from Atrial Arrhythmias with or without AAD</measure>
    <time_frame>From 3 months (blanking period) to 24 months after the first ablation procedure</time_frame>
    <description>Freedom from documented symptomatic atrial arrhythmias &gt;30 seconds at 24 months after 1 or several ablation procedures with or without antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia Burden</measure>
    <time_frame>From 3 months (blanking period) to 12 months and 24 months after the first ablation procedure</time_frame>
    <description>Number of Registrations with Remote Heart Monitor / Number of Registrations with Atrial Arrhythmia with Remote Heart Monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Recurrens</measure>
    <time_frame>From first ablation procedure to 24 months</time_frame>
    <description>Time from first ablation procedure to first documented recurrens of atrial arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Repeat Procedures</measure>
    <time_frame>12 and 24 months after the first ablation procedure</time_frame>
    <description>Number of repeat procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures: Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Overall Score and Subscale Scores</measure>
    <time_frame>Baseline, 12 and 24 months after the first ablation procedure</time_frame>
    <description>AFEQT is a 21 questions atrial fibrillation specific health related quality of life questionnaire. Overall Score (calculated from 18 of the questions) and subscale scores in three domains: symptoms, daily activities, and treatment concern. Score ranges from 0 to 100 points. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures: RAND 36 (Research ANd Development) 36 All Domains</measure>
    <time_frame>Baseline,12 and 24 months after the first ablation procedure</time_frame>
    <description>RAND 36 (developed by RAND corporation) is a 36 questions health related quality of life questionnaire. The RAND 36 is divided into 8 domains: Physical functioning, role physical, role emotional, bodily pain, vitality, general health, social functioning and mental health. Score range from 0 to 100 points. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events/ Complications</measure>
    <time_frame>12 and 24 months after the first ablation procedure</time_frame>
    <description>Complications related to the ablation procedure: Cardiac perforation, stroke, transitory ischemic attack (TIA), systemic embolic events, atrio-esophageal fistula, major bleeding, atrioventricular block, groin hematoma requiring vascular surgery or extended hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Mortality</measure>
    <time_frame>12 and 24 months after the first ablation procedure</time_frame>
    <description>Number of Participants With All-cause Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Time from start of groin punction to withdrawal of the catheters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>Immediately after the procedure</time_frame>
    <description>Total fluoroscopy time during the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation plus substrate modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary vein isolation plus ablation of low voltage areas in the left atrium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radio frequency ablation</intervention_name>
    <description>Two different radio frequency ablation procedures</description>
    <arm_group_label>Pulmonary vein isolation</arm_group_label>
    <arm_group_label>Pulmonary vein isolation plus substrate modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ECG-documented persistent or long-standing persistent atrial fibrillation according to
             European Society of Cardiology (ESC) definition

          2. Symptoms e. g. palpitations, dyspnea, tiredness that is due to the atrial
             fibrillation.

          3. Suitable candidate for catheter ablation.

          4. Tried one or more antiarrhythmic drugs or unwilling to try antiarrhythmic drugs

          5. Age â‰¥18 years.

        Exclusion Criteria:

          1. LA dimension &gt;55 mm as determined by an echocardiography within the previous year

          2. Acute coronary syndrome or coronary artery bypass surgery within 12 weeks

          3. Severe aortic or mitral valvular heart disease using the ESC guidelines

          4. Congenital heart disease

          5. Prior surgical or percutaneous AF ablation procedure or atrioventricular-nodal
             ablation

          6. Medical condition likely to limit survival to &lt; 1 year

          7. New York Heart Association (NYHA) class IV heart failure symptoms

          8. Contraindication to oral anticoagulation

          9. Renal failure requiring dialysis

         10. AF due to reversible cause

         11. Pregnant and fertile women without anticonception

         12. History of non-compliance to medical therapy

         13. Unable or unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Jensen-Urstad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikola Drca, MD</last_name>
    <phone>+46858580000</phone>
    <email>nikola.drca@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Paul Nordin, MD</last_name>
    <phone>+46858580000</phone>
    <email>astrid.paul-nordin@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Jensen-Urstad, Professor</last_name>
      <phone>0046-8-58580000</phone>
      <email>mats.jensen-urstad@sll.se</email>
    </contact>
    <investigator>
      <last_name>Mats Jensen-Urstad, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004 Aug 31;110(9):1042-6. Epub 2004 Aug 16.</citation>
    <PMID>15313941</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.</citation>
    <PMID>27567408</PMID>
  </reference>
  <reference>
    <citation>Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis AB, Davies DW, Day JD, d'Avila A, Natasja de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T; Document Reviewers:. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018 Jan 1;20(1):e1-e160. doi: 10.1093/europace/eux274. Review.</citation>
    <PMID>29016840</PMID>
  </reference>
  <reference>
    <citation>Tilz RR, Rillig A, Thum AM, Arya A, Wohlmuth P, Metzner A, Mathew S, Yoshiga Y, Wissner E, Kuck KH, Ouyang F. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol. 2012 Nov 6;60(19):1921-9. doi: 10.1016/j.jacc.2012.04.060. Epub 2012 Oct 10.</citation>
    <PMID>23062545</PMID>
  </reference>
  <reference>
    <citation>Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, Komatsu Y, Roten L, Jadidi A, Linton N, Pedersen M, Daly M, O'Neill M, Knecht S, Weerasooriya R, Rostock T, Manninger M, Cochet H, Shah AJ, Yeim S, Denis A, Derval N, Hocini M, Sacher F, Haissaguerre M, Jais P. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol. 2015 Feb;8(1):18-24. doi: 10.1161/CIRCEP.114.001943. Epub 2014 Dec 20.</citation>
    <PMID>25528745</PMID>
  </reference>
  <reference>
    <citation>Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, Schweikert RA, Saliba W, Cummings J, Burkhardt JD, Bhargava M, Belden WA, Abdul-Karim A, Natale A. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005 Jan 18;45(2):285-92.</citation>
    <PMID>15653029</PMID>
  </reference>
  <reference>
    <citation>Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009 Apr 7;119(13):1758-67. doi: 10.1161/CIRCULATIONAHA.108.811877. Epub 2009 Mar 23.</citation>
    <PMID>19307477</PMID>
  </reference>
  <reference>
    <citation>Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, Piedra C, Hindricks G, Piorkowski C. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2014 Oct;7(5):825-33. doi: 10.1161/CIRCEP.113.001251. Epub 2014 Aug 23.</citation>
    <PMID>25151631</PMID>
  </reference>
  <reference>
    <citation>Yagishita A, Sparano D, Cakulev I, Gimbel JR, Phelan T, Mustafa H, De Oliveira S, Mackall J, Arruda M. Identification and electrophysiological characterization of early left atrial structural remodeling as a predictor for atrial fibrillation recurrence after pulmonary vein isolation. J Cardiovasc Electrophysiol. 2017 Jun;28(6):642-650. doi: 10.1111/jce.13211. Epub 2017 May 29.</citation>
    <PMID>28387462</PMID>
  </reference>
  <reference>
    <citation>Schreiber D, Rieger A, Moser F, Kottkamp H. Catheter ablation of atrial fibrillation with box isolation of fibrotic areas: Lessons on fibrosis distribution and extent, clinical characteristics, and their impact on long-term outcome. J Cardiovasc Electrophysiol. 2017 Sep;28(9):971-983. doi: 10.1111/jce.13278. Epub 2017 Jul 5.</citation>
    <PMID>28635186</PMID>
  </reference>
  <reference>
    <citation>Kottkamp H, Bender R, Berg J. Catheter ablation of atrial fibrillation: how to modify the substrate? J Am Coll Cardiol. 2015 Jan 20;65(2):196-206. doi: 10.1016/j.jacc.2014.10.034. Review.</citation>
    <PMID>25593061</PMID>
  </reference>
  <reference>
    <citation>Phlips T, Taghji P, El Haddad M, Wolf M, Knecht S, Vandekerckhove Y, Tavernier R, Duytschaever M. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the 'CLOSE'-protocol. Europace. 2018 Nov 1;20(FI_3):f419-f427. doi: 10.1093/europace/eux376.</citation>
    <PMID>29315411</PMID>
  </reference>
  <reference>
    <citation>El Haddad M, Taghji P, Phlips T, Wolf M, Demolder A, Choudhury R, Knecht S, Vandekerckhove Y, Tavernier R, Nakagawa H, Duytschaever M. Determinants of Acute and Late Pulmonary Vein Reconnection in Contact Force-Guided Pulmonary Vein Isolation: Identifying the Weakest Link in the Ablation Chain. Circ Arrhythm Electrophysiol. 2017 Apr;10(4). pii: e004867. doi: 10.1161/CIRCEP.116.004867.</citation>
    <PMID>28381417</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Jensen-Urstad</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Catheter ablation</keyword>
  <keyword>Low voltage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

